BTIG Reiterates Humacyte Buy Recommendation, Sees 615.56% Upside Potential

BTIG reiterates a Buy recommendation for Humacyte (HUMA) with an average one-year price target of $8.01/share, a 615.56% increase from its latest closing price. The projected annual revenue is $85MM, and the projected annual non-GAAP EPS is -$0.04. There are 264 funds or institutions reporting positions in Humacyte, with an average portfolio weight of 0.02%. The put/call ratio of HUMA is 0.16, indicating a bullish outlook.